The total return over the past 12 months is +6.59% vs. +16.94% for the S&P 500. So far it's up -2.91% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +6.59% | +34.95% | +2.19% | +2.93% | +6.44% | N/A |
| Total Return CAGR | +6.59% | +34.95% | +2.19% | +2.93% | +6.44% | N/A |
| Revenue CAGR | N/A | +97.62% | +85.17% | +26.25% | +13.92% | +0.29% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Arbutus Biopharma Corp (ABUS)
| Year | Start price | End price | ABUS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $4.81 | $4.67 | (2.91%) | +14.51% | (17.42%) |
| 2025 | $3.27 | $4.81 | +47.09% | +17.72% | +29.37% |
| 2024 | $2.50 | $3.27 | +30.80% | +24.89% | +5.91% |
| 2023 | $2.33 | $2.50 | +7.30% | +26.19% | (18.89%) |
| 2022 | $3.89 | $2.33 | (40.10%) | (18.17%) | (21.93%) |
| 2021 | $3.55 | $3.89 | +9.58% | +28.74% | (19.16%) |
| 2020 | $2.78 | $3.55 | +27.70% | +18.37% | +9.33% |
| 2019 | $3.83 | $2.78 | (27.42%) | +31.22% | (58.64%) |
| 2018 | $5.05 | $3.83 | (24.16%) | (4.56%) | (19.60%) |
| 2017 | $2.45 | $5.05 | +106.12% | +21.70% | +84.42% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
